Patents Examined by Paul Martin
  • Patent number: 10006840
    Abstract: The present invention provides methods and compositions for separating cells from a sample containing erythrocytes. The method is for recovering desired cells from a sample containing the desired cells, erythrocytes and undesired cells comprising: a) contacting the sample with a composition, said composition comprising: i) an erythrocytes aggregation reagent ii) at least one antigen recognizing moiety coupled to a magnetic particle, wherein said particle with said at least one antigen recognizing moiety specifically binds to at least one antigen specific for one or more undesired cellular components; b) applying simultaneously i) gravity sedimentation for sedimentation of erythrocytes and ii) a magnetic field gradient to said sample for immobilizing said magnetic particle generating a pellet and a supernatant phase, and c) recovering the desired cells from the supernatant phase. Compositions for the use within the present method are also disclosed.
    Type: Grant
    Filed: November 20, 2012
    Date of Patent: June 26, 2018
    Assignee: Miltenyi Biotec GmbH
    Inventors: Burgund Kauling, Volker Huppert
  • Patent number: 9958432
    Abstract: The invention relates to systems and methods for studying patient cancer samples in cis-co-culture with stromal cells from the same patient. For example, the invention provide systems and methods for testing therapeutic agents in vitro in an environment that simulates an in vivo environment to identify agents that are therapeutically effective for the patient.
    Type: Grant
    Filed: September 19, 2014
    Date of Patent: May 1, 2018
    Assignee: LYNX BIOSCIENCES, INC.
    Inventors: Chorom Pak, Edmond Wai Keung Young, Natalie Callander, David James Beebe, Shigeki Miyamoto
  • Patent number: 9931381
    Abstract: Physiologically acceptable anti-biofilm compositions comprising Serratia peptidase and optionally one or more of bromelain, papain and a fibrinolytic enzyme. Additional components can include antimicrobials, antibiotics, antifungals, herbals, chelating agents, lactoferrin and related compounds, minerals, surfactants, binders, and fillers useful for the inhibition and treatment of gastrointestinal biofilms in humans. Physiologically acceptable anti-biofilm compositions containing these enzymes are useful in the inhibition, reduction and/or treatment of biofilms such as in the ear, vagina, joints, bones, gut, surgical sites and other locations, and are useful for the inhibition, reduction and/or treatment of associated systemic symptoms caused by biofilm associated microorganisms.
    Type: Grant
    Filed: November 23, 2010
    Date of Patent: April 3, 2018
    Assignee: PROTHERA, INC.
    Inventor: Stephen Francis Olmstead
  • Patent number: 9920344
    Abstract: The present invention relates to a method for producing a composition containing isomaltulose from a substrate containing sucrose comprising the steps of: a) contacting the substrate containing sucrose with a particulate carrier-immobilized sucrose isomerase biomass and b) obtaining a composition containing isomaltulose, characterized in that the median particle size d(0.5) of the carrier-immobilized sucrose isomerase biomass is from 370 to 550 ?m. The carrier can be an alginate or a polyvinyl alcohol carrier.
    Type: Grant
    Filed: July 17, 2014
    Date of Patent: March 20, 2018
    Assignee: SÜDZUCKER AKTIENGESELLSCHAFT MANNHEIM/OCHSENFURT
    Inventors: Wolfgang Wach, Thomas Rose
  • Patent number: 9909158
    Abstract: A method of producing a sugar liquid from a cellulose-containing biomass includes (1) hydrolyzing a cellulose-containing biomass using a filamentous fungus-derived cellulose and carrying out solid-liquid separation into a sugar liquid and a hydrolysis residue; (2) washing the hydrolysis residue in (1) using an aqueous alkaline solution and an aqueous inorganic salt solution independently and recovering, as a washing liquid, the filamentous fungus-derived cellulase adsorbed to the hydrolysis residue; and (3) filtering the washing liquid in (2) through an ultrafiltration membrane to recover a sugar liquid as a permeate and the filamentous fungus-derived cellulase as a non-permeate.
    Type: Grant
    Filed: July 1, 2013
    Date of Patent: March 6, 2018
    Assignee: Toray Industries, Inc.
    Inventors: Chiaki Yamada, Hiroyuki Kurihara, Katsushige Yamada
  • Patent number: 9878070
    Abstract: Provided is a malleable implant configured to fit at or near a bone defect site to promote bone growth, the malleable implant comprising: a biodegradable polymer, mineral particles, and an oxysterol, the implant configured to become moldable upon being wetted with a fluid. Methods of making and use are further provided.
    Type: Grant
    Filed: June 17, 2015
    Date of Patent: January 30, 2018
    Inventors: Benjamin T. Reves, David S. Scher, Susan J. Drapeau, Roger E. Harrington, Jerbrena C. Jacobs
  • Patent number: 9879304
    Abstract: The present invention provides a method of quantifying the activity of a protein modifying enzyme in a sample, comprising: (i) grouping modified peptides from a first sample and modified peptides from a second sample into a single group according to one of the following parameters: (a) modified peptides having a modification site that is modified by the same protein modifying enzyme; or (b) modified peptides having a modification site that is part of the same modification motif; (ii) calculating enrichment of the modified peptides from the first sample compared to the modified peptides from the second sample in the group; and (iii) calculating the statistical significance of said enrichment; wherein a statistically significant enrichment is indicative of a protein modifying enzyme being activated in the first sample compared to the second sample. In some embodiments, the method further comprises identifying modified peptides in a first sample and a second sample using mass spectrometry (MS) prior to step (i).
    Type: Grant
    Filed: March 8, 2013
    Date of Patent: January 30, 2018
    Assignee: Queen Mary & Westfield College, University of London
    Inventor: Pedro Rodriguez Cutillas
  • Patent number: 9872502
    Abstract: The present invention relates to fungi of Acremonium spp, wherein said fungi are purified or isolated from plants of the Brachiaria-Urochloa complex and wherein, when said fungi are inoculated into a plant, said plant has improved resistance to diseases and/or pests relative to an uninocualated control plant. The present invention also relates to plants inoculated with such fungi, products produced by the fungi and related genes, proteins and methods.
    Type: Grant
    Filed: June 1, 2012
    Date of Patent: January 23, 2018
    Assignee: Agriculture Victoria Services Pty Ltd
    Inventors: German Carlos Spangenberg, Kathryn Michaela Guthridge
  • Patent number: 9862980
    Abstract: The present invention provides a process for enzyme mediated hydrolysis of biomass for production of soluble sugars, wherein the said process comprises of steady addition of small portions of biomass to enzyme solution, enabling rapid solubilization of biomass. The process used for enzymatic saccharification allows for increased biomass loading, enzyme recycle and mitigation of substrate and product inhibitory effect. The recycling of unhydrolysed biomass along with soluble enzyme ensures complete reuse of the said enzyme for effective repeated hydrolysis thereby increasing the overall productivity of enzyme used.
    Type: Grant
    Filed: January 16, 2015
    Date of Patent: January 9, 2018
    Assignees: Department of Biotechnology, Institute of Chemical Technology
    Inventors: Arvind Mallinath Lali, Annamma Anil Odaneth, Sachinkumar Hiraman Birhade, Juliet Joanna Victoria, Sneha Chandrakant Sawant
  • Patent number: 9855305
    Abstract: The present invention relates to a pharmaceutical composition containing a combination of vitamins, specific salts of calcium, magnesium, and iron, probiotics and prebiotics, which prevents the occurrence of adverse effects associated with long-term use of proton-pump inhibitors (PPIs). This effect is achieved by restoring all nutrient deficiencies and rectifying the intestinal flora imbalance caused by this type of drugs, particularly in patients with gastroesophageal reflux disease and Zollinger-Ellison syndrome.
    Type: Grant
    Filed: March 29, 2016
    Date of Patent: January 2, 2018
    Assignee: Companion Therapeutics LLC
    Inventors: Julio César Villamil Torres, Camilo Rey Ferro
  • Patent number: 9857359
    Abstract: Use of cereblon-associated proteins as biomarkers for clinical sensitivity to cancer, inflammatory diseases, and patient response to drug treatment.
    Type: Grant
    Filed: June 28, 2013
    Date of Patent: January 2, 2018
    Assignee: CELGENE CORPORATION
    Inventors: Peter H. Schafer, Rajesh Chopra, Antonia Lopez-Girona, Laura Corral, Maria Yinglin Wang, Pilgrim Jackson
  • Patent number: 9857387
    Abstract: The invention provides a method of detecting abnormal entry of gastrointestinal contents into the respiratory tract of a patient. The method comprises orally administering to a subject formulation comprising a detectable label that is not absorbed from the gastrointestinal tract but can be absorbed from the respiratory tract. The extent of the gastrointestinal contents entering the respiratory tract can be estimated by measuring the level of the detectable label in a body fluid, e.g., blood or urine.
    Type: Grant
    Filed: February 18, 2015
    Date of Patent: January 2, 2018
    Assignees: Aradigm Corporation, The Regents of The University of California
    Inventors: Igor Gonda, Homer A. Boushey
  • Patent number: 9850504
    Abstract: Described is a method for the production of 3-buten-2-one comprising the enzymatic conversion of 4-hydroxy-2-butanone into 3-buten-2-one by making use of an enzyme catalyzing 4-hydroxy-2-butanone dehydration, wherein said enzyme catalyzing 4-hydroxy-2-butanone dehydration is (a) a 3-hydroxypropiony-CoA dehydratase (EC 4.2.1.116), (b) a 3-hydroxybutyryl-CoA dehydratase (EC 4.2.1.55), (c) an enoyl-CoA hydratase (EC 4.2.1.17), (d) a 3-hydroxyoctanoyl-[acyl-carrier-protein] dehydratase (EC 4.2.1.59), (e) a crotonyl-[acyl-carrier-protein] hydratase (EC 4.2.1.58), (f) a 3-hydroxydecanoyl-[acyl-carrier-protein] dehydratase (EC 4.2.1.60), (g) a 3-hydroxypalmitoyl-[acyl-carrier-protein] dehydratase (EC 4.2.1.61), (h) a long-chain-enoyl-CoA hydratase (EC 4.2.1.74), or (i) a 3-methylglutaconyl-CoA hydratase (EC 4.2.1.18). The produced 3-buten-2-one can be further converted into 3-buten-2-ol and finally into 1,3-butadiene.
    Type: Grant
    Filed: July 2, 2014
    Date of Patent: December 26, 2017
    Assignees: Scientist of Fortune, S.A., Global Bioenergies
    Inventors: Philippe Marliere, Maria Anissimova, Mathieu Allard
  • Patent number: 9840727
    Abstract: Methods are provided for the prognosis, diagnosis and treatment of various pathological states, including cancer, chemotherapy resistance and dementia associated with Alzheimer's disease. The methods provided herein are based on the discovery that various proteins with a high level of sialylation are shown herein to be associated with disease states, such as, cancer, chemotherapy resistance and dementia associated with Alzheimer's disease. Such methods provide a lysosomal exocytosis activity profile comprising one or more values representing lysosomal exocytosis activity. Also provided herein, is the discovery that low lysosomal sialidase activity is associated with various pathological states. Thus, the methods also provide a lysosomal sialidase activity profile, comprising one or more values representing lysosomal sialidase activity. A lysosomal sialidase activity profile is one example of a lysosomal exocytosis activity profile.
    Type: Grant
    Filed: June 20, 2016
    Date of Patent: December 12, 2017
    Assignee: St. Jude Children's Research Hospital
    Inventors: Ida Annunziata, Alessandra D'Azzo, Shai White-Gilbertson
  • Patent number: 9835614
    Abstract: System and Method for measuring the growth of a bacterial culture and its response to one or more antimicrobials using measurement of mass of individual microbes. Methods include periodic sampling, determining change in mass and concentration, and comparing growth rates of cultures in nutrient broth vs. mixtures containing various antibiotic mixtures. A number of antimicrobials can be compared in one measurement by multiplexing or using multiple sensors to measure in parallel. Growth and antibiotic efficacy can be assessed at low concentrations at the onset of growth, typically within 1 to 2 hours.
    Type: Grant
    Filed: September 8, 2014
    Date of Patent: December 5, 2017
    Assignee: Affinity Biosensors, LLC
    Inventors: Ken Babcock, Cynthia Schneider
  • Patent number: 9791456
    Abstract: The present relates to methods for detecting DNA damage in subjects treated with an ATR inhibitor. More specifically, this invention relates to a method for measuring changes in levels of ?H2AX and/or pChk1Ser345 in, e.g., surrogate tissue cells, following ex vivo stimulation with a DNA damaging agent.
    Type: Grant
    Filed: February 27, 2015
    Date of Patent: October 17, 2017
    Assignees: Vertex Pharmaceuticals Incorporated, University of Newcastle Upon Tyne
    Inventors: Susanna Falcon, Philip Reaper, John Pollard, Nicola Curtin, Fiona Middleton, Tao Chen
  • Patent number: 9763969
    Abstract: The present invention describes compositions and related methods and kits for treating a variety of inflammatory conditions and infections. The therapeutic compositions include certain hyaluronidases capable of generating hyaluronan disaccharides when combined with hyaluronan, and/or the hyaluronan disaccharides themselves, and/or inflammatory hyaluronidase inhibitors. The invention further discloses the use of hyaluronidase inhibitors to treat certain infections in an individual.
    Type: Grant
    Filed: April 3, 2014
    Date of Patent: September 19, 2017
    Assignee: Cedars-Sinai Medical Center
    Inventors: George Liu, Pierre Kyme
  • Patent number: 9758438
    Abstract: The present invention provides novel phosphate-solubilizing fungal strains, compositions comprising novel phosphate-solubilizing fungal strains, and methods of using novel phosphate-solubilizing fungal strains to increase the availability of phosphate for plant uptake in soil. In some embodiments, one or more of the novel phosphate-solubilizing fungal strains is coated onto a seed.
    Type: Grant
    Filed: May 13, 2016
    Date of Patent: September 12, 2017
    Assignee: NOVOZYMES BIOAG A/S
    Inventors: David Greenshields, Shelagh Steckler, Kari Priest, Caressa Caldwell, Michael Frodyma
  • Patent number: 9737591
    Abstract: Physiologically acceptable anti-biofilm compositions comprising Serratia peptidase and optionally one or more of bromelain, papain and a fibrinolytic enzyme. Additional components can include antimicrobials, antibiotics, antifungals, herbals, chelating agents, lactoferrin and related compounds, minerals, surfactants, binders, and fillers useful for the inhibition and treatment of gastrointestinal biofilms in humans. Physiologically acceptable anti-biofilm compositions containing these enzymes are useful in the inhibition, reduction and/or treatment of biofilms such as in the ear, vagina, joints, bones, gut, surgical sites and other locations, and are useful for the inhibition, reduction and/or treatment of associated systemic symptoms caused by biofilm associated microorganisms.
    Type: Grant
    Filed: March 25, 2011
    Date of Patent: August 22, 2017
    Assignee: PROTHERA, INC.
    Inventor: Stephen Francis Olmstead
  • Patent number: 9738883
    Abstract: The present invention claims a novel process for the production and purification of microbial collagenase (Microbial Collagenase EC 3.4.24.3) produced by the non-pathogenic aerobic bacterium Vibrio alginolyticus chemovar. iophagus (NCIMB Number: 1 1038, synonym LMG 3418, hereinafter called Vibrio alginolyticus), which said process provides high production levels of collagenase with a stable, reproducible, cheap fermentation process. The collagenase produced from Vibrio alginolyticus according to the process described herein also presents a specific activity superior to that of other microbial collagenases, is stable in aqueous solution, and can be frozen without significant damage.
    Type: Grant
    Filed: April 17, 2013
    Date of Patent: August 22, 2017
    Assignee: FIDIA FARMACEUTICALS S.P.A.
    Inventors: Susanna Vaccaro, Michele Caputo, Christian Cuppari, Giovanni Gennari